TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.26
-0.02 (-7.14%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.28
Open0.27
Bid0.26 x 0
Ask0.27 x 0
Day's Range0.26 - 0.28
52 Week Range0.19 - 0.55
Volume457,247
Avg. Volume252,236
Market Cap34.212M
Beta-0.89
PE Ratio (TTM)N/A
EPS (TTM)-0.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.38
  • FSCWire7 days ago

    Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers provides an update on the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

  • FSCWire23 days ago

    Theralase Increases Revenue 22% for 2017 Financial Statements

    In the US, revenue decreased 37% to $261,833 from $416,812 while, international revenue increased 76% to $138,665 from $78,900. The increase in Canadian and international revenue in 2017 and the corresponding decrease in US revenue is attributable to the Company’s sales and marketing team focusing on the Canadian and international markets.

  • ACCESSWIRElast month

    Today’s Research Reports on Eyecarrot Innovations, Antibe Therapeutics, Emblem and Theralase Technologies

    NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRElast month

    Canadian Exchanges Stock Scanner Titan Medical, Patient Home Monitoring, Zecotek Photonics, and Theralase Technologies

    LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Medical Devices industry: Titan Medical, Patient Home Monitoring, Zecotek Photonics, and Theralase Technologies. The TSX Venture Exchange gained 5.05 points, or 0.63%, to finish at 802.60. Today's stocks of interest consist of: Titan Medical Inc. (TSX: TMD), Patient Home Monitoring Corporation (TSX-V: PHM), Zecotek Photonics Inc. (TSX-V: ZMS), and Theralase Technologies Inc. (TSX-V: TLT).

  • FSCWirelast month

    Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, provides an update on the Phase Ib NMBIC clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

  • Baystreetlast month

    Medical Technology Advancements Spur New Opportunity For Investment

    The U.S. health care market is the largest in the world by market size. Health Access reports that ...

  • Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
    FSCWire2 months ago

    Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced the filing of a US patent application detailing the discovery of a significant increase in the destruction of cancer cells, when Theralase’s patented anti-cancer technology is combined with cannabinoids. In preclinical experiments, Theralase scientific researchers combined a specific cannabinoid with their patented anti-cancer Photo Dynamic Therapy (“PDT”) technology to produce an unexpected synergistic effect in the destruction of rat glioma brain cancer cells (“RG2”).

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Emblem, 3D Signatures, ABcann Global and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
    FSCWire2 months ago

    Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that its lead PDC, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to effectively destroy human brain cancer stem cells. Despite tremendous advances in cancer therapy over the last ten years, resistance to treatment and high rates of recurrence remain stubbornly common.

  • FSCWire3 months ago

    Rutherrin(R) Technology Granted Allowance for Canadian Patent

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF),  a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that it has been notified that it has been granted allowance for a Canadian patent to issue later this year for Rutherrin® (TLD-1433 PDC combined with transferrin) for the treatment of cancer. “Allowance of one of the Company’s key patents is timely as we approach the completion of enrollment in our Phase Ib trial for Non-Muscle Invasive Bladder Cancer (“NMIBC”).

  • FSCWire3 months ago

    Theralase Announces Settlement Agreement with Ontario Securities Commission

    Theralase Technologies Inc. (the “Company”) (TSXV: TLT) (OTCQX: TLTFF) announced today that the Company and Roger Dumoulin-White, former Chairman, President and Chief Executive Officer, have entered into a settlement agreement (“Agreement”) with Staff of the Ontario Securities Commission (“OSC”).

  • FSCWire3 months ago

    Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers, announced today that the sixth patient in a nine patient Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) was enrolled and treated on February 7, 2018, using the Company’s anti-cancer technology. The Study is being used to evaluate the Company’s lead PDC drug for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue).

  • FSCWire4 months ago

    Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    January 18, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 10, 2018, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.

  • FSCWire4 months ago

    Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 11, 2017, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.

  • Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
    FSCWire4 months ago

    Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer has announced an optimization to the delivery schedule of its proprietary anti-cancer vaccine, increasing its efficacy in the destruction of brain cancer. The anti-cancer vaccine was evaluated in a rat glioma (“RG2”) animal model, an established model of Glioblastoma Multiforme (“GBM”), a deadly form of human brain cancer.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Emblem Corp., Cronos Group Inc., Calyx Bio-Ventures Inc. and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE6 months ago

    Theralase Discovers Theralase(R) Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments

    TORONTO, ON / ACCESSWIRE / November 30, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQX: TLTFF ) ( FSE: TTX ), a leading biotech company ...

  • ACCESSWIRE6 months ago

    Theralase Increases Revenue 12% for 3Q2017 Financial Statements

    TORONTO, ON / ACCESSWIRE / November 29, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • ACCESSWIRE6 months ago

    Theralase Therapeutic Laser Technology Enhances Cancer Destruction

    TORONTO, ON / ACCESSWIRE / November 27, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • ACCESSWIRE6 months ago

    Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer

    TORONTO, ON / ACCESSWIRE / November 22, 2017 / Theralase Technologies Inc. ('' Theralase® '' or the '' Company '') ( TSX-V: TLT ) ( OTCQX: TLTFF ) ( FSE: TTX ), a leading biotech company focused on the ...

  • ACCESSWIRE6 months ago

    Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug

    TORONTO, ON / ACCESSWIRE / November 21, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on the ...

  • ACCESSWIRE6 months ago

    Theralase Discovers New Anti-Cancer Vaccine

    TORONTO, ON / ACCESSWIRE / November 20, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • CNW Group6 months ago

    IIROC Trading Resumption - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - Trading resumes in: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Resumption (ET): 13:30  IIROC can make a decision to impose a temporary suspension (halt) ...

  • PR Newswire6 months ago

    IIROC Trading Resumption - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - Trading resumes in: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Resumption (ET): 13:30  IIROC can make a decision to impose a temporary suspension (halt) ...

  • CNW Group6 months ago

    IIROC Trading Halt - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - The following issues have been halted by IIROC: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Reason: Pending Company Contact Halt Time (ET): 11:18 AM IIROC ...